The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
Takeda Pharmaceutical said on May 10 that it has submitted positive interim results from its PI/II immunogenicity and safety study being conducted in Japan for US partner Moderna’s COVID-19 vaccine, which was filed for Japanese approval in early March. The…
To read the full story
Related Article
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…